Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immutep Ltd ( (AU:IMM) ) has issued an announcement.
Immutep Ltd’s recent presentation at their Annual General Meeting 2025 provided an update on the company’s business activities. The presentation emphasized the company’s ongoing efforts and strategic plans, although it included forward-looking statements subject to various risks and uncertainties. Stakeholders are advised to consider these factors carefully, as actual results may differ from current expectations.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd operates in the biotechnology industry, focusing on empowering the immune system to combat cancer and autoimmune diseases. The company is listed on ASX and NASDAQ under the symbols IMM and IMMP, respectively.
Average Trading Volume: 2,185,450
Technical Sentiment Signal: Sell
Current Market Cap: A$390.1M
See more insights into IMM stock on TipRanks’ Stock Analysis page.